A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors January 11, 2018 Type of Cancer Solid Tumor Sponsor Tesaro Protocol Number 4020-01-001 To Learn More Call 201-510-0910
